Diagnostic value of miRNA-133b and miRNA-150 for non-small cell lung cancer / 肿瘤研究与临床

ABSTRACT

Objective:To investigate the expressions of miRNA-133b (miR-133b) and miRNA-150 (miR-150) in non-small cell lung cancer (NSCLC) and their clinical significances.Methods:Thirty patients with NSCLC who underwent surgery and were pathologically diagnosed in the First People's Hospital of Lianyungang from June 2018 to June 2019 were selected. Before surgery, 10 ml fasting peripheral blood of patients was collected in the morning. The fresh cancer tissues, adjacent tissues (distance from cancer tissues ≤ 3 cm), normal lung tissues (distance from cancer tissues > 5 cm) were collected after surgery. Thirty people who had a physical examination during the same period were served as the healthy control group, and 10 ml fasting peripheral blood was collected in the morning. Real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) was used to detect the relative expressions of miR-133b and miR-150 in the serum of the two groups of subjects and the tissues of NSCLC patients. The relationships between serum miR-133b and miR-150 levels and the clinical features in NSCLC patients were analyzed. The pathological diagnosis was used as the gold standard, and the receiver operating characteristic (ROC) curve was used to determine the efficacy of miR-133b and miR-150 in diagnosing NSCLC.Results:In NSCLC patients, the relative expressions of miR-133b in cancer tissues, adjacent tissues and normal lung tissues were 0.55±0.17, 0.68±0.11 and 0.69±0.12, and the expression of miR-133b in cancer tissues was lower than that in adjacent tissues and normal lung tissues (both P < 0.01). The relative expressions of miR-150 in cancer tissues, adjacent tissues and normal lung tissues were 1.19±0.14, 1.13±0.13 and 1.09±0.12, and there was no significant difference in the expression of miR-150 between cancer tissues and adjacent tissues ( t = 1.98, P = 0.051), and the expression of miR-150 in cancer tissues was higher than that in normal lung tissues ( t = 3.06, P = 0.003). The relative expression of plasma miR-133b in NSCLC patients was lower than that in healthy controls (0.43±0.11 vs. 0.55±0.16, t = 3.68, P<0.05); the relative expression of plasma miR-150 was higher than that in healthy controls (1.14±0.13 vs. 1.04±0.12, t = -3.18, P < 0.05). The expression level of miR-133b in the serum of NSCLC patients was related to lymph node metastasis ( P = 0.003), but not related to the patients' gender, age, pathological type, and TNM stage (all P > 0.05). The expression level of miR-150 in serum of NSCLC patients was not related to the clinicopathological characteristics (all P > 0.05). According to the ROC curve, the area under the curve of miR-133b and miR-150 in serum of NSCLC patients were 0.732 and 0.726, and the area under the curve of the combined detection of the two was 0.811. Conclusions:The expression levels of miR-133b in cancer tissues and serum of NSCLC patients decrease, and the expression levels of miR-150 increase. The expression trends of the two in cancer tissues and serum of NSCLC patients are consistent. miR-133b may be related to the malignant degree, invasion and metastasis of NSCLC. miR-133b and miR-150 may become molecular markers for the diagnosis of NSCLC, and the combined detection of the two has higher diagnostic efficiency.